Background: Fever and neutropenia (FN) clinical decision rules (CDRs) are recommended to help distinguish children with cancer at high and low risk of severe infection. The aim of this study was to validate existing pediatric FN CDRs designed to stratify children with cancer at high or low risk of serious infection or medical complication. Methods: Pediatric CDRs suitable for validation were identified from a literature search. Relevant data were extracted from an existing data set of 650 retrospective FN episodes in children with cancer. The sensitivity and specificity of each of the CDR were compared with the derivation studies to assess reproducibility. Results: Six CDRs were identified for validation: 2 were designed to predict bacteremia and 4 to predict adverse events. Five CDRs exhibited reproducibility in our cohort. A rule predicting bacteremia had the highest sensitivity (100%; 95% confidence interval (CI): 93%-100%) although poor specificity (17%), with only 15% identified as low risk. For adverse events, the highest sensitivity achieved was 84% (95% CI: 75%-90%), with specificity of 29% and 27% identified as low risk. A rule intended for application after a 24-hour period of inpatient observation yielded a sensitivity of 80% (95% CI: 73-86) and specificity of 46%, with 44% identified as low risk. Conclusions: Five CDRs were reproducible, although not all can be recommended for implementation because of either inadequate sensitivity or failure to identify a clinically meaningful number of low-risk patients.
T he risk of infection in the setting of chemotherapy-induced neutropenia, heralded by fever, remains an unavoidable complication of the treatment of childhood cancer. Treatment strategies for fever and neutropenia (FN) that are tailored to an individual's likelihood of severe infection, by incorporating risk stratification, are well described. 1 To help differentiate children at low and high risk of severe infection, pediatric FN clinical decision rules (CDRs) have been recommended as an important adjunct to the risk stratification process.
2 Children accurately identified as low risk may benefit from reduced intensity antibiotic therapy and early hospital discharge, while additional supportive care measures and heightened vigilance may avoid clinical deterioration in high-risk patients. 3 There are 4 key components to CDR development: derivation, internal validation, external validation and implementation and impact analysis. 4 Before a CDR, especially one targeting pediatric FN, can be implemented into practice, it should undergo evaluation in a population external to the derivation data set to ensure that it is safe and reliable. 5 While many of the pediatric FN CDRs that have undergone external validation show some reproducibility, most result in lower sensitivity compared with the derivation study. [6] [7] [8] [9] [10] This highlights the importance of detailed local external validation to provide clinicians with a realistic expectation of the predictive performance of a CDR in their own population. Such validations will identify CDR limitations and should guide implementation of low-risk treatment programs that incorporate safeguards against potential failures of the CDR.
Using an existing local data set of consecutive episodes of outpatient onset FN, retrospectively collected to validate the Predicting Infectious ComplicatioNs in Children with Cancer (PIC-NICC) CDR, the aim of this study was to validate additional published pediatric FN CDRs designed to stratify children with cancer or hematologic malignancy at high or low risk of serious infection or medical complication. 10 The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of each of these rules applied to our retrospective data set were compared with the derivation studies.
METHODS

Identification of Clinical Decision Rules for Validation
OR children OR paediatric OR pediatric) was also conducted (nonEnglish studies and abstracts were excluded). The date of the search was April 18, 2016. Studies were excluded if there was insufficient information available from the existing retrospective data set to validate the rule or if no rule was described. Rules that included presence of central venous access device (CVAD) as predictor of outcome were also excluded as 95% of children in the existing data set had a CVAD, and this was deemed a priori as nondiscriminatory.
10
Data Collection
External validation was performed using an existing local data set of retrospectively identified episodes of outpatient-onset FN in children and adolescents with cancer or hematologic malignancy. 10 This local data set will be herein described as validation cohort. Detailed methodology for patient episode identification and data collection is described elsewhere. 10 Briefly, consecutive episodes of outpatient-onset FN in children and adolescents (age <19 years) with cancer and receiving chemotherapy or hematopoetic stem cell transplant at The Royal Children's Hospital (RCH), Melbourne, were included in the study (November 2011 to June 2015). Demographic, FN episode and clinical outcome data were obtained from electronic records and entered into REDCap database. 12 Data were collected by a research assistant blinded to the CDRs included in this analysis. Patients were excluded if they were already receiving empiric or targeted treatment antibiotics or onset of the FN episode occurred in hospital.
Definitions
Fever was defined as a single tympanic temperature greater than, or equal to, 38°C, and neutropenia was defined as an absolute neutrophil count less than 1000/mm 3 . Bacteremia was defined as a recognized pathogen (including viridans group streptococci in the setting of mucosal barrier injury or neutropenia) cultured from one or more blood cultures or common commensal bacteria cultured from 2 or more blood cultures drawn on separate occasions. 13 For validation, the variable or outcome definition used in the derivation study was applied to our validation cohort. An exception to this was "bacteremia," where the above international consensus definition was applied to avoid incorrectly attributing single positive blood culture with a common commensal as a true bacteremia. Where no definition was provided, variables or outcomes followed international consensus recommendations. 13, 14 The date and time bacteremia episodes were known were extracted from the electronic pathology database. For all other clinical and microbiologically defined infections (MDIs) and for medical complications such as intensive care unit (ICU) admission, the date and time the infection or event was documented in the medical record were used.
Statistical Analysis
The sensitivity, specificity, PPV and NPV for each rule were calculated in our validation cohort using both the inclusion and exclusion criteria from our existing data set 10 and those criteria restricted to that described by the derivation studies. Confidence intervals around sensitivity and specificity were calculated using hybrid Wilson/ Brown method. To ensure consistency, confidence intervals from the derivation studies were recalculated from available data. For rules that stratified patients into more than 2 groups (ie, low, intermediate and high risk), we combined intermediate and low risk into a single low-risk group. The sensitivity and specificity of the Swiss Pediatric Oncology Group (SPOG) rule was determined by combining the information on episodes with adverse event known at day 2, with the results of prediction on the remaining episodes. 9 Continuous data were presented as median and interquartile range. Fisher exact test was used to estimate P values for categorical data, including comparison of sensitivity and specificity between derivation and validation cohorts. The Newcombe-Wilson test with continuity correction was used for difference between proportions. A CDR was considered reproducible if there was no significant difference in either the sensitivity or specificity between the derivation and validation cohorts. All tests were 2-tailed, and a P value of <0.05 was considered to be statistically significant.
RESULTS
A total of 21 potentially relevant studies describing pediatric FN CDRs or risk factors for severe infection were identified in published systematic reviews 6, 11 and a further 6 were identified in our search of the literature. [15] [16] [17] [18] [19] [20] Of these 27 studies, 6 described CDRs that were suitable for validation in our data set.
9,21-25 Eleven could not be validated, as there was insufficient information available from the existing data set. 16, 21, [26] [27] [28] [29] [30] [31] [32] [33] [34] A further 8 studies described individual variables for infection or adverse outcome in the absence of a defined rule. [17] [18] [19] [20] [35] [36] [37] [38] In the remaining 2, a CVAD was used as a predictor of outcome, 39 and validation of the PICNICC CDR using this data set had already been completed. 10 Details of study design and demographic data from the validation cohort and the included derivation studies are available in Table, Supplemental Digital Content 1, http://links.lww.com/INF/ C843. Where sufficient data were available for comparison, there was no significant difference in sex, proportion with relapsed disease or death in the validation cohort compared with any of the derivation studies. There were significantly more patients with hematologic malignancy in the validation cohort compared with the Alexander et al 22 and Rackoff et al 25 derivation studies. Bacteremia occurred in significantly fewer FN episodes in our validation cohort compared with the SPOG, 9 Baorto et al 23 and Rackoff et al 25 derivation studies. Table 1 provides details of the inclusion and exclusion criteria, as well as description of the CDR variables and predicted outcomes. A different definition of fever, albeit slightly, was used in all 6 studies and almost all excluded patients with hematopoetic stem cell transplant. The number of clinical variables included in the CDRs ranged from 1 to 9 (1 variable in 2 CDR, 2 in 1, 4 in 2 and 9 in 1). Two CDRs were designed to predict bacteremia only, of which a definition was provided for only 1. 23,25 The remaining 4 CDRs predicted composite outcomes encompassing a varying combination of microbiologic infection, sepsis, pneumonia, severe medical complication or death.
Results of the sensitivity, specificity, PPV and NPV analyses for each CDR are shown in Table 2 . The clinical impact of each rule was calculated using both the existing data set inclusion criteria (validation cohort) and the derivation study inclusion criteria (restricted validation cohort). Notably, for each of the 6 rules, there was very little difference in the validation results obtained using the different inclusion criteria, with broad overlap of the 95% confidence intervals for all results (Figures 1 and 2) . Bacteremia was observed in significantly fewer FN episodes in our validation cohort compared with the 2 derivation studies that specifically investigated this outcome 23, 25 (Table 2) . For the remainder, there was no significant difference in the proportion of patients with the specific outcome investigated.
A direct comparison of sensitivity and specificity between the derivation studies and both the validation cohort and restricted validation cohort is also shown in Table 2 . There was a significant difference in both sensitivity and specificity between the Hakim et al 21 derivation and both validation cohorts. For the remaining 5 CDRs, there was no difference between sensitivity for 1 CDR (Klaassen), specificity in 1 (SPOG) or both sensitivity and specificity in 3 (Rackoff, Baorto, and Alexander). 22, 23, 25 The CDR with the highest observed in 5 of the CDRs, with no significant difference in both sensitivity and specificity between the derivation and validation cohorts in 3 of these. 22, 23, 25 Although often attributed as a cause of discordant derivation and validation study results, we also showed that using inclusion and exclusion criteria that varied to that of the derivation study appeared to have little impact.
Three of the reproducible rules were designed to predict a composite outcome of "adverse outcome" or "serious infection." 9, 22, 24 While the definition for these composite outcomes varied between studies, all 3 included at least bacteremia, other bacterial infection and death. The CDR by Klaassen et al 24 had the highest sensitivity in validation cohort (84%) but the lowest specificity (28%). The inclusion of the subjective outcome of "life-threatening complication as judged by the treating physician," may have contributed to the lower sensitivity observed in the validation results of the SPOG and Alexander CDR. 9, 22 Despite this, the SPOG rule, in particular, produced a sensitivity of up to 80% with a specificity of 46%, correctly identifying 86% of low-risk patients. This CDR is unique in that it is applied after a 24-hour period of inpatient observation.
The remaining 2 reproducible CDRs in our validation cohort were designed to predict bacteremia. 23, 25 Notably, the proportion of bacteremia episodes in the local validation cohort (9%) was significantly lower than both these derivation studies. This difference can be attributed to the strict exclusion of common commensals identified on single blood cultures to avoid incorrectly attributing these as a true bacteremia. 35 The rule developed by Baorto et al produced the highest sensitivity and PPV in the validation cohort, approaching 100%. Not surprisingly, the specificity was poor, with very few episodes being identified as low risk. These data suggest that implementation of this CDR in our population, while reassuring given the very high sensitivity, would be difficult to justify as only 33 out of 177 patients per year would qualify as low risk and, therefore, appropriate for consideration of reduced-intensity therapy.
While this is the first study to validate these international CDRs in Australia, 5 have previously undergone validation in populations external to the derivation studies. 9, [22] [23] [24] [25] Most of these validation studies demonstrate at least some degree of overlap in confidence intervals for either sensitivity or specificity suggesting validity. [7] [8] [9] [40] [41] [42] The 3 rules derived in the United States 22, 23, 25 have been shown to be effective in Europe and in the United Kingdom 7, 9, 40, 42 and the Canadian rule 24 in Europe and in the United States. 7, 9, 41 However, until now, the SPOG rule has not been tested outside of Europe. 8 The CDRs included in this study were validated using an existing data set designed to validate the PICNICC CDR. 15 This rule was developed from an individual participant data meta-analysis and included data from 4 of the rules validated in this study. 9, 21, 22, 24 For the prediction of MDI, the recalibrated PICNICC rule did not perform as well in our population as compared with the derivation study with a sensitivity and specificity of 78.4% and 39.8%, respectively. 10 However, when using methodology described by Ammann et al 9 for the SPOG rule, the sensitivity of the PICNICC rule improved to 88%, further highlighting the importance of an overnight period of observation.
Although this study was performed using an existing, retrospective data set, it includes a contemporary cohort of consecutive episodes of FN. Given the reliance on the existing data set, sample size calculations were not performed. For validation of a CDR in a new population, a sample size that includes 100 outcome events and 100 nonoutcome events has been recommended. 43 Based on this, an appropriate sample size was achieved for validation of 3 of the 6 CDRs, of which 2 predicted adverse outcome 9, 22 and 1 predicted significant bacterial infection. 24 With regard to validation of the SPOG rule, it is possible that the date and time that nonbacteremia microbiologically and clinically documented infections, as well as medical complications such as admission to ICU, were known were earlier than what was documented in the medical records. This would have underestimated the sensitivity of the SPOG rule that takes into account the number of infections or medical complications known at time of assessment. Our study is unique in that it compared validation results using differing inclusion criteria. The similarities in results between the 2 validation cohorts suggests that the impact of differences in inclusion and exclusion criteria between derivation and validation studies may have been overstated, although this will vary from study to study. The rationale for risk prediction in FN is to tailor treatment strategies according to the likelihood of having a documented infection or adverse outcome. This will avoid over treatment of children with viral illness or noninfective causes of fever and, conversely, enable targeted treatment and observation strategies for high-risk patients to avoid severe complication such as late-onset sepsis, ICU admission and death. A systematic review of oral and outpatient antibiotic regimens for children with low-risk FN which analyzed data from 13 randomized controlled trials and 24 prospective observational studies concluded that both oral antibiotics and outpatient therapy are safe alternatives to standard care. 1 The rate of modification from reduced intensity therapy back to standard inpatient care appears to be affected by the time of discharge, with a significant reduction in requirements for pathway modifications when patients were discharged after 48 hours compared with immediately (2.2% versus 14%). Deviations from low-risk treatment were also significantly less frequent in centers using stringent risk tools compared with centers using unnamed and unvalidated tools (7% versus 19.1%). 1 Although none of the validated rules included in this study have been subject to formal implementation and impact analysis, it is conceivable that a rule such as SPOG rule, which requires a 24-hour period of observation, may result in less failure. 9 When implemented at the time of hospital presentation with FN, the sensitivity of a CDR to predict infection or adverse event is considered to be of greatest importance. While this is traditionally at the expense of specificity, the ability of the test to correctly identify those without the disease needs to be sufficiently high to make implementation of the rule worthwhile. Our validation study has identified 5 internationally derived pediatric FN CDRs that are reproducible. However, although reproducibility was observed in these studies, not all can be recommended for implementation based on either inadequate sensitivity or failure to identify a sufficient number of patients who are at low risk. Of the rules validated in this study, the SPOG rule arguably exhibits the best balance between sensitivity and specificity in our population and may facilitate the implementation of a low-risk FN program that is safe, practical and will avoid the over treatment of as many children as possible. Further research is required to assess the clinical, psychosocial and economic impact of such a program and to ensure that the strengths and the weakness of the CDR continue to be evaluated.
